How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? the example of Sunitinib for first-line treatment of metastatic renal cell carcinoma

Value in Health

Volumn 13, Issue 6, 2010, Pages 837-845

  Chabot, Isabelle ^a   Rocchi, Angela ^b  

^a PFIZER INC   (United States)

^b Axia Research   (Canada)

Author keywords

access; cost effectiveness ratio; decision making; economic; kidney cancer; oncology; reimbursement; renal cell carcinoma; sunitinib

Indexed keywords

ALPHA INTERFERON; SUNITINIB;

CANADA; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; HUMAN; KIDNEY CARCINOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; ONCOLOGY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; REVIEW; SIDE EFFECT;

EID: 77956373891     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2010.00738.x     Document Type: Review

References (47)

1. Rocchi A, Menon D, Verma S, Miller E. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. Value Health 2008 11 : 771 783.
2. Canadian Cancer Society. Canadian Cancer Statistics 2008. 2008. Available from: http://www.cancer.ca/Canada-wide/About%20cancer/Cancer%20statistics/ ∼/media/CCS/Canada%20wide/Files%20List/English%20files%20heading/ pdf%20not%20in%20publications%20section/ Canadian%20Cancer%20Society%20Statistics%20PDF%202008-614137951.ashx [Accessed September 29, 2008 A, La VC. Epidemiology of renal-cell carcinoma. J Nephrol 1997 10 : 93 106.
3. Drucker BJ. Renal cell carcinoma: current status and future prospects. Cancer Treat Rev 2005 31 : 536 545.
4. Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. Curr Treat Options Oncol 2003 4 : 385 390.
5. Nelson EC, Evans CP, Lara PN Jr. Renal cell carcinoma: current status and emerging therapies. Cancer Treat Rev 2007 33 : 299 313.
6. Hotte S, Waldron T, Canil C, Winquist E. Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: a systematic review and practice guideline. Can Urol Assoc J 2007 1 : 27 38.
7. Coppin C, Porzsolt F, Autenrieth M, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2008 (4 CD001425.
8. Bellmunt J. Current treatment in advanced renal cell carcinoma (RCC): impact of targeted therapies in the management of RCC. Eur Urol Suppl 2007 6 : 484 491.
9. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006 295 : 2516 2524.
10. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006 24 : 16 24.
11. Canadian Pharmacists Association. Compendium of pharmaceuticals and specialties 2008. SUTENT Product Monograph. Ottawa. 2008.
12. Canadian Agency for Drugs and Technologies in Health. CEDAC final recommendation on reconsideration and reasons for recommendation - Sunitinib malate. Available from: http://www.cadth.ca/media/cdr/complete/cdr-complete- Sutent-e-April-26-2007%20.pdf [Accessed April 26, 2007 RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007 356 : 115 124.
13. Pfizer Canada Inc. Sutent Product Monograph. 2008.
14. Committee to Evaluate Drugs (CED) - Ministry of Health and Long-Term Care. Recommendations and reasons - Sunitinib (for metastatic renal cell carcinoma). 2008. Available from: http://www.healthgovonca/english/providers/ program/drugs/ced/pdf/sunitinib-mrccpdf [Accessed September 29, 2008 2008 2 : 175 182.
15. Amato RJ. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 2005 16 : 7 15.
16. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005 353 : 2477 2490.
17. Health Canada. Summary basis of decision - Nexavar. Available from: http://www.hc-sc.gc.ca/dhp-mps/alt-formats/hpfb-dgpsa/pdf/prodpharma/ sbd-smd-2007-nexavar-102070-eng.pdf [Accessed May 22, 2007 MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. Oxford : Oxford University Press, 1996.
18. Pfizer Inc. Lajolla Science Center, San Diego, Protocol A6181034 (Interim Analysis 3), data on file. 2007.
19. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004 22 : 454 463.
20. Statistics Canada. Life Tables, Canada, Provinces and Territories 1995-1997. Ottawa, ON : Statistics Canada, 2002.
21. Canadian Agency for Drugs and Technologies in Health. CEDAC final recommendation on reconsideration and reasons for recommendation - Sorafenib. Available from: http://www.cadth.ca/media/cdr/complete/cdr-complete-Nexavar-Fe- 28-07.pdf [Accessed February 28, 2007 I, LeLorier J, Blackstein ME. The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumour. Eur J Cancer 2008 44 : 972 977.
22. Rosenberg JE, Motzer RJ, Michaelson MD, et al. Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma (mRCC): updated results of two phase II trials and prognostic factor analysis for survival. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I 2007 25 : 5095.
23. Motzer RJ, Figlin RA, Hutson TE, et al. Sunitinib versus interferon-alfa (INF-a) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I 2007 25 : 5024.
24. Pfizer Inc. Sunitinib malate A6181034, Clinical Study Report (Interim Analysis 2). 2006.
25. Pfizer Inc. Lajolla Science Center, San Diego, Protocol RTKC-0511-014, data on file. 2007.
26. Statistics Canada. Consumer Price Index (CPI), Health and Personal Care Component. 2007. Table 326-0001. Available from: http://cansim2.statcan.ca/cgi- win/cnsmcgi.pgm [Accessed May 8, 2010 2007.
27. Cancer Care Ontario. CCO formulary - drug monographs for healthcare professionals - ALDESLEUKIN. 2006. Available from: http://www.cancercare.on.ca/ pdfchemo/aldes-rcc.pdf [Accessed September 29, 2008 A, Verma S. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. Support Care Cancer 2006 14 : 917 927.
28. Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada. Ottawa : Canadian Agency for Drugs and Technologies in Health, 2006. Repor t No.: 3rd Edition.
29. Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon-alfa (IFN-a) as first line treatment of metastatic renal cell carcinoma. J Clin Oncol 2008 26 (Suppl. Abstract 5024.
30. Remak E, Charbonneau C, Negrier S, et al. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol 2008 26 : 3995 4000.
31. Laupacis A. Economic evaluations in the Canadian common drug review. Pharmacoeconomics 2006 24 : 1157 1162.
32. Sculpher M, Claxton K. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty - when is there sufficient evidence? Value Health 2005 8 : 433 446.
33. Levinson W, Laupacis A. A call for fairness in formulary decisions. Arch Intern Med 2006 166 : 16 18.
34. Sinclair S, Hagen NA, Chambers C, et al. Accounting for reasonableness: exploring the personal internal framework affecting decisions about cancer drug funding. Health Policy 2008 86 : 381 390.
35. Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006 11 : 90 5.
36. Berry SR, Hubay S, Soibelman H, Martin DK. The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: a qualitative study. BMC Health Serv Res 2007 7 : 193.
37. Booth CM, Dranitsaris G, Gainford MC, et al. External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer. BMC Cancer 2007 7 : 110.
38. Ekos Research Associates Inc. Evaluation of the first year of operation for the Common Drug Review. Final report. 2005.
39. Williams I, McIver S, Moore D, Bryan S. The use of economic evaluations in NHS decision-making: a review and empirical investigation. Health Technol Assess 2008 12 (7 iii, ix x 1 175.
40. Pearson SD, Rawlins MD. Quality, innovation, and value for money: NICE and the British National Health Service. JAMA 2005 294 : 2618 2622.
41. National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal. London : National Institute for Clinical Excellence, 2004.
42. Mason AR, Drummond MF. NHS reimbursement of new cancer drugs: is NICE getting nastier? Value Health 2008 11 : A11.
43. National Institute for Clinical Excellence. NICE announces measures on end of life medicines. 2008. Available from: http://www.nice.org.uk/media/6C4/ 6C/2008066MeasuresOnLifeMedicines.pdf [Accessed March 30, 2009 2009. Available from: http://www.nice.org.uk/media/420/AD/ 2009009DraftNICEGuidanceDrugsRenalCancerv2.pdf [Accessed March 30, 2009 MF, Sculpher MJ, Torrance JGW, et al. Methods for the Economic Evaluation of Health Care Programmes (3rd ed.). Oxford : Oxford University Press, 2005.
44. Detsky AS, Laupacis A. Relevance of cost-effectiveness analysis to clinicians and policy makers. JAMA 2007 298 : 221 224.
45. Harris AH, Hill SR, Chin G, et al. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. Med Decis Making 2008 28 : 713 722.
46. Canadian Agency for Drugs and Technologies in Health. CEDAC final recommendation on reconsideration and reasons for recommendation - Sunitinib. Available from: http://www.cadth.ca/media/cdr/complete/cdr-complete-Sutent- March-28-07.pdf [Accessed March 28, 2007 CM, Urbach DR, Ray DJ, et al. Bias in published cost-effectiveness studies: systematic review. BMJ 2006 332 : 699 703.
47. Ontario Ministry of Health and Long-Term Care. Ontario Drug Benefit Formulary/Comparative Drug Index. Ontario : Ontario Ministry of Health and Long-Term Care, 2007.